Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million.

This bill establishes a $6 million pilot program to study psilocybin therapy for behavioral health conditions like depression and anxiety through New Jersey hospitals. It directs the Department of Health to select participating hospitals across three regions (Central, Northern, Southern) to conduct FDA- and DEA-compliant research, with oversight from a new advisory board. The program aims to evaluate whether a future statewide system for safe, legal psilocybin therapy could be developed, focusing on treatment-resistant depression and other conditions. The bill was withdrawn after being approved as part of P.L.2025, c.296, meaning it is now law but no longer pending.